Examining COMMD10 Expression in Tumors to Predict Response to Radiotherapy
A Bidirectional Cohort Study of COMMD10 Expression in Tumor Tissues for Predicting Radiosensitivity
This study is trying to see if measuring a protein in tumor samples can help predict which cancer patients will respond well to radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06165224 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the expression levels of the copper metabolism domain protein 10 (COMMD10) in tumor tissues to predict radiosensitivity in patients with various types of cancers. By analyzing tumor samples from patients with nasopharyngeal carcinoma, head and neck tumors, lung cancer, and others, the study seeks to establish a biomarker that can indicate which patients are likely to respond to radiotherapy. The goal is to improve treatment outcomes by identifying patients who may benefit from radiotherapy sensitization agents or alternative therapies. This research addresses a significant gap in the ability to predict radiation resistance, which currently limits the effectiveness of radiotherapy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with specific types of cancers who are indicated for radiotherapy.
Not a fit: Patients with contraindications to radiotherapy or those with certain medical conditions that could complicate treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better treatment strategies for cancer patients by identifying those who are likely to benefit from radiotherapy.
How similar studies have performed: While the approach of identifying biomarkers for radiosensitivity is not novel, the specific focus on COMMD10 as a predictive marker is relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years old; 2. Voluntarily sign informed consent; 3. Nasopharyngeal carcinoma, head and neck tumor, lung cancer, breast cancer, stomach cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, bile duct cancer, cervical cancer, prostate cancer confirmed by pathology; 4. Measurable tumor lesions according to RECIST v1.1 criteria; 5. Patients with radiation therapy indications and voluntarily accept radiotherapy; 6. ECOG PS score: 0/1. Exclusion Criteria: 1. There are contraindications to radiotherapy; 2. Pathological sections could not be obtained; 3. Presence of metal metabolism-related diseases such as Wilson's disease; 4. Merge other tumors (has cured basal cell or squamous cell cancer, and cervical cancer in situ except 5); 5. Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. "For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor health status, uncontrolled diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness;" 6. The investigator judged that he was not suitable to participate in the study.
Where this trial is running
Guangzhou, Guangdong
- Nanfang hospital, Southern medical university — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jian Guan, M.D.
- Email: guanjian5461@163.com
- Phone: +86-13632102247
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.